Is pentostatin , cyclophosphamide , and rituximab an active , well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia?
PCR is safe and effective in previously treated patients with CLL. In comparison with our prior two-drug regimen, we find that rituximab did not seem to add significantly to the toxicity, but did appear to confer a survival advantage. Based on these results, we are currently studying PCR as initial therapy for patients with CLL.
All children should have the benefit of the most sensitive imaging available, including CT, to detect tumor spread.